We are live on ! Find out more
EAM

Eventide Asset Management Portfolio holdings

AUM $7.48B
1-Year Est. Return 104.76%
This Fund
S&P 500
This Quarter Est. Return
+37.69%
1 Year Est. Return
+104.76%
3 Year Est. Return
+313.12%
5 Year Est. Return
+388.67%
10 Year Est. Return
+3,437.54%
AUM
$7.48B
AUM Growth
+$1.44B
Cap. Flow
-$77.6M
Cap. Flow %
-1.04%
Top 10 Hldgs %
23.83%
Holding
336
New
58
Increased
161
Reduced
69
Closed
35
Avg Time Held
6.6 quarters
Top 10 Avg Time Held
4.2 quarters
Top 20 Avg Time Held
4.6 quarters

Top Buys

Rank Stock Value
1
AVLN icon
Avalyn Pharma
AVLN
+$39.7M
2
CDNS icon
Cadence Design Systems
CDNS
+$29.6M
3
RELY icon
Remitly
RELY
+$27.3M
4
DELL icon
Dell
DELL
+$25.5M
5
FITB icon
Fifth Third Bancorp
FITB
+$25.3M

Top Sells

Rank Stock Value
1
XMTR icon
Xometry
XMTR
+$57.8M
2
PLD icon
Prologis
PLD
+$56.1M
3
GH icon
Guardant Health
GH
+$44M
4
AXSM icon
Axsome Therapeutics
AXSM
+$44M
5
GLBE icon
Global E Online
GLBE
+$37.6M

Sector Composition

Rank Sector Weight
1 Healthcare 36.37%
2 Technology 22.57%
3 Industrials 20.48%
4 Energy 5.51%
5 Utilities 4.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BBIO icon
76
BridgeBio Pharma
BBIO
$12.4B
$32.6M 0.44%
437,130
– –
2023 Q1
13 quarters
ROL icon
77
Rollins
ROL
$15.4B
$32.1M 0.43%
767,984
+14,485
+2% +$740K
2023 Q3
11 quarters
HLI icon
78
Houlihan Lokey
HLI
$9.01B
$32M 0.43%
239,140
+3,004
+1% +$443K
2023 Q3
11 quarters
OVID icon
79
Ovid Therapeutics
OVID
$428M
$31.8M 0.42%
11,812,241
+1,895,330
+19% +$4.89M
2025 Q4
2 quarters
NRIX icon
80
Nurix Therapeutics
NRIX
$2.36B
$31.5M 0.42%
1,297,893
– –
2025 Q4
2 quarters
VRT icon
81
Vertiv
VRT
$90.5B
$30.8M 0.41%
92,404
-2,606
-3% -$827K
2025 Q3
3 quarters
COHR icon
82
Coherent
COHR
$56.4B
$30.6M 0.41%
77,487
+40,466
+109% +$14.3M
2025 Q4
2 quarters
FITB icon
83
Fifth Third Bancorp
FITB
$45.4B
$30.5M 0.41%
539,040
+499,580
+1,266% +$25.3M
2025 Q2
4 quarters
ARWR icon
84
Arrowhead Research
ARWR
$8.27B
$30.2M 0.4%
370,000
– –
2025 Q4
2 quarters
RELY icon
85
Remitly
RELY
$4.95B
$29.9M 0.4%
+1,332,003
New +$27.3M
2026 Q2
0 quarters
MSCI icon
86
MSCI
MSCI
$40.9B
$29.4M 0.39%
52,607
+1,539
+3% +$898K
2023 Q2
12 quarters
HBAN icon
87
Huntington Bancshares
HBAN
$30.7B
$29.2M 0.39%
1,641,712
-891,790
-35% -$14.7M
2024 Q3
7 quarters
IRON icon
88
Disc Medicine
IRON
$2.18B
$28.9M 0.39%
395,651
+79
+0% +$5.43K
2025 Q1
5 quarters
ULS icon
89
UL Solutions
ULS
$14.3B
$28.6M 0.38%
281,062
+13,288
+5% +$1.26M
2026 Q1
1 quarter
ROK icon
90
Rockwell Automation
ROK
$47.8B
$27.9M 0.37%
56,458
+446
+0.8% +$194K
2025 Q1
5 quarters
CHWY icon
91
Chewy
CHWY
$7.92B
$27.8M 0.37%
1,413,874
+1,584
+0.1% +$36K
2025 Q1
5 quarters
SNX icon
92
TD Synnex
SNX
$22B
$27M 0.36%
+100,983
New +$24.3M
2026 Q2
0 quarters
CGON icon
93
CG Oncology
CGON
$5.55B
$26.3M 0.35%
369,839
-146
-0% -$9.54K
2025 Q4
2 quarters
BKR icon
94
Baker Hughes
BKR
$55.6B
$25.6M 0.34%
459,110
+21,093
+5% +$1.33M
2025 Q3
3 quarters
WCN icon
95
Waste Connections
WCN
$38.8B
$25.4M 0.34%
152,351
-157,576
-51% -$24.9M
2016 Q4
38 quarters
ISRG icon
96
Intuitive Surgical
ISRG
$149B
$24.1M 0.32%
60,634
+692
+1% +$302K
2019 Q2
28 quarters
SHW icon
97
Sherwin-Williams
SHW
$78.2B
$24.1M 0.32%
70,111
-1,013
-1% -$324K
2020 Q1
25 quarters
AMLX icon
98
Amylyx Pharmaceuticals
AMLX
$3.41B
$23.8M 0.32%
1,327,536
-186,422
-12% -$2.88M
2025 Q3
3 quarters
IEX icon
99
IDEX
IEX
$17.4B
$23.5M 0.31%
103,503
+2,610
+3% +$552K
2019 Q3
27 quarters
ORKA icon
100
Oruka Therapeutics
ORKA
$5.25B
$22.8M 0.31%
+240,000
New +$16M
2026 Q2
0 quarters
2 3
4
5 6

Similar funds

S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
CCM
Check Capital Management Costa Mesa, California $7.52B AUM 15.3% 1-Year Est. Return
O
Ossiam Paris, France $7.54B AUM 50.81% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
FPP
Findlay Park Partners London, United Kingdom $7.41B AUM 26.32% 1-Year Est. Return
RIG
RiverFront Investment Group Richmond, Virginia $7.56B AUM 23.82% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

Eventide Asset Management's Q2 2026 Portfolio in Review

As of Q2 2026, Eventide Asset Management held 336 positions worth $7.48B, up 24% from $6.05B the previous quarter. Its ten largest holdings account for 24% of the portfolio.

Eventide Asset Management's Q2 2026 filing shows 58 new, 161 increased, 69 reduced and 35 closed positions. Its largest new stake was Avalyn Pharma: 1,375,486 shares worth $45.3M. The largest sale was Xometry, an estimated $57.8M.

By sector, the portfolio is most concentrated in Healthcare at 36% of assets, down from 39% a quarter earlier, followed by Technology and Industrials.

  • Eventide Asset Management's largest Q2 2026 buy was Avalyn Pharma: 1,375,486 shares worth $45.3M.
  • Eventide Asset Management added most to Cadence Design Systems in Q2 2026, an estimated $29.6M increase.
  • Eventide Asset Management's biggest Q2 2026 reduction was Xometry, cutting an estimated $57.8M.
  • Eventide Asset Management fully exited Prologis in Q2 2026, selling an estimated $56.1M.
  • Eventide Asset Management's ten largest holdings make up 24% of its $7.48B portfolio in Q2 2026.
  • Eventide Asset Management opened 58 new positions and closed 35 in Q2 2026.
  • Eventide Asset Management's portfolio value rose 24% quarter-over-quarter to $7.48B.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.